Moderna Stock Price and Forecast: MRNA collapses as US and UK go back to normal life

Moderna stock slides again as investors lose faith.
MRNA shares also suffering as UK fully opens up and Biden says normal is on the way.
Moderna lacks alternative revenue streams.

Ivan Brian FXStreet

FXStreet had turned bearish on this stock after resutls in November, but the emergence of the Omicron variant did change things somewhat. Moderna (MRNA) shares spiked as panic gripped markets and Omicron was an unknown entity.

The shares quickly spiked to nearly $380 from a post-earnings low of $220. However, Moderna put in a bearish shooting star candle that signified impending losses. The news was finally confirmed in our view when on December 20 Moderna said its jab was effective against Omicron. Moderna shares spiked intraday but actually closed 6% lower as investors ditched the name.

The reason as we now apparently know is that it appears Omicron is much less serious that other variants. More transmissable, yes, but the variant results in much fewer hospitalizations. Experts have now come to the conclusion that this is the end game for covid. This will be the final covid winter. This appears to have gotten confirmtaion from the UK yesterday as emabttled Prime Minister Johnson gets to luckily deflect attention away from him by announcing an end to restrictions. In the US President Biden says things are nearly back to normal. Europe is a little further behind, but already some countries such as Ireland are significantly easing restrictions.

Moderna Stock News

Moderna cracked below key support at $188 when it lost nearly 7% yesterday. Markets are not in a charitable mood, and increased attention is now being focused on potential short names and dumping high growth stocks. FXStreet has identified before the one-trick pony that MRNA potentially is. It is hugely reliant on covid vaccines for revenue. It does have some other products in the pipeline as shown below, but none are yet commercial.

Source: Moderna www.modernatx.com/pipeline

Moderna Stock Forecast

$188.40 was a big level going back to February of last year. The stock eventually broke above in summer 2021 and staged a successful pullback test before marching higher. Now that it is broken, the next target is $157.70 and then some decent volume support at $147. Resistance at $211 is the short-term pivot.

Moderna (MRNA) chart, daily

Like this article? Help us with some feedback by answering this survey:

Author

Ivan Brian

FXStreet

Ivan Brian started his career with AIB Bank in corporate finance and then worked for seven years at Baxter. He started as a macro analyst before becoming Head of Research and then CFO.

AUD/USD hovers around 0.7000, over one-week low ahead of RBA decision

AUD/USD consolidates the previous day's losses to an over one-week low, holding steady around 0.7000 during the Asian session on Tuesday ahead of the RBA rate decision. Meanwhile, the US Dollar remains depressed as hopes for a diplomatic resolution to end the US-Iran war counter Fed hike bets amid market anxiety ahead of the US midterm elections, further supporting the currency pair.

USD/JPY fails near 159.00 amid weak USD, intervention risks

USD/JPY edges lower during Tuesday’s Asian session, reversing part of the previous day's gains to 158.00 as the US Dollar remains depressed amid hopes for Iran diplomacy and ahead of US midterm elections. Meanwhile, intervention risks support the Japanese Yen, though the uncertainty over the timing of the next BoJ rate hike caps gains. This keeps the pair confined within a familiar range and warrants caution before placing directional bets.

Gold consolidates near $3,950 as Fed hike bets counter weak USD ahead of US elections

Gold holds steady around $3,950 through Tuesday’s Asian session, consolidating the previous day's recovery gains from the lowest level since October 2025, touched last week. Hopes for Iran optimism keep the safe-haven US Dollar depressed, which, along with anxiety ahead of US midterm elections, supports the bullion. However, Fed rate-hike bets and a modest bounce in US bond yields cap gains for the non-yielding yellow metal.

RBA expected to raise interest rate to 4.85%

The Reserve Bank of Australia will announce its monetary policy decision on Tuesday and is widely anticipated to raise the Official Cash Rate by 25 basis points to 4.85% from 4.6%. If the RBA delivers as expected, it will be the fifth interest rate hike of 2026, and the OCR will hit an 18-year high.

Strong iPhone sales fortify Apple's Q4 result

A robust fourth-quarter for Apple's iPhone sales helped the tech titan beat Wall Street's consensus on Monday. Apple reported $57.58 billion in iPhone sales in Q4, beating the average analyst estimate by more than a billion. However, AAPL stock shed close to 4% afterhours despite the top and bottom line beat.

The 2% inflation target came from a throwaway remark. It now moves trillions

The Federal Reserve's 2% inflation goal grew out of an off-the-cuff remark by a New Zealand politician in 1988. Bond investors still price long-term US debt as if 2% holds, so a change in how the Fed measures inflation would move markets.